Agentix announced it has entered into a WW exclusive license and technology transfer agreement with the National Health Research Institutes (NHRI) of Taiwan ROC. According to the press release, Agentix will license several NHRI patents and patent applications to develop, manufacture, and commercialize DBPR211 for the treatment of human disease. For context, DBPR211 is a peripherally restricted cannabinoid receptor 1 antagonist that has completed preliminary pre-clinical and in vivo testing requirements. Agentix intends to begin Ph1 trials by September 2022. Below, FENIX provides context and insights for the announcement.